Elevation Point Wealth Partners LLC Invests $868,000 in Dianthus Therapeutics, Inc. $DNTH

Elevation Point Wealth Partners LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 8,902 shares of the company’s stock, valued at approximately $868,000.

Several other large investors also recently bought and sold shares of DNTH. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $27,000. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC raised its stake in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Simon Read sold 2,778 shares of Dianthus Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director owned 2,778 shares in the company, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Adam M. Veness sold 16,167 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president directly owned 3,833 shares in the company, valued at approximately $423,086.54. The trade was a 80.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 287,084 shares of company stock worth $29,615,923. Insiders own 3.02% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Wedbush boosted their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and an average target price of $124.27.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $110.07 on Tuesday. Dianthus Therapeutics, Inc. has a one year low of $22.81 and a one year high of $117.88. The firm has a market cap of $6.02 billion, a PE ratio of -26.52 and a beta of 1.22. The firm’s 50 day moving average price is $101.30 and its 200-day moving average price is $85.62.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.